Understanding and restoring dopaminergic function in fibromyalgia patients using a mindfulness-based psychological intervention: a [18F]-DOPA PET study. Study protocol for the FIBRODOPA study-a randomized controlled trial

K Ledermann, R von Känel, C Berna, H Sprott, M Burckhardt, J Jenewein, E L Garland, C Martin-Sölch, K Ledermann, R von Känel, C Berna, H Sprott, M Burckhardt, J Jenewein, E L Garland, C Martin-Sölch

Abstract

Background: Fibromyalgia (FM) is a very prevalent and debilitating chronic pain disorder that is difficult to treat. Mindfulness-based techniques are regarded as a very promising approach for the treatment of chronic pain and in particular FM. The Mindfulness-Oriented Recovery Enhancement (MORE) intervention, a mindfulness-based group intervention, has shown beneficial effects in opioid-treated chronic pain patients, including reduced pain severity, functional interference, and opioid dosing, by restoring neurophysiological and behavioral responses to reward. The first evidence for a hypodopaminergic state and impaired reward processing in FM has been reported. However, little is known about its impact on dopamine (DA) function and in particular with regard to DA responses to monetary reward in FM. The aim of the present study protocol is to evaluate if MORE is able to restore the DA function in FM patients, in particular with regard to the DA responses to reward, and to reduce pain and mood complaints in FM.

Methods: The present study is a multi-center interventional RCT with 3 time points: before the intervention, after completion of the intervention, and 3 months after completion of the intervention. Sixty-four FM patients will be randomly assigned to either the MORE intervention (N = 32) or a non-intervention control group (N = 32). Additionally, a comparison group of healthy women (N = 20) for PET measures will be enrolled and another group of healthy women (N = 15) will do the ambulatory assessments only. The MORE intervention consists of eight 2-h-long group sessions administered weekly over a period of 8 weeks. Before and after the intervention, FM participants will undergo [18F] DOPA positron emission tomography (PET) and functional MR imaging while performing a reward task. The primary outcome will be endogeneous DA changes measured with [18F] DOPA PET at baseline, after the intervention (after 8 weeks for the non-intervention control group), and at 3 months' follow-up. Secondary outcomes will be (1) clinical pain measures and FM symptoms using standardized clinical scales; (2) functional brain changes; (3) measures of negative and positive affect, stress, and reward experience in daily life using the ambulatory assessment method (AA); and (4) biological measures of stress including cortisol and alpha-amylase.

Discussion: If the findings of this study confirm the effectiveness of MORE in restoring DA function, reducing pain, and improving mood symptoms, MORE can be judged to be a promising means to improve the quality of life in FM patients. The findings of this trial may inform health care providers about the potential use of the MORE intervention as a possible non-pharmacological intervention for FM.

Trial registration: ClinicalTrials.gov NCT04451564 . Registered on 3 July 2020. The trial was prospectively registered.

Keywords: Dopamine; F-18 DOPA PET; Fibromyalgia; Mindfulness-Oriented Recovery Enhancement; Reward; fMRI.

Conflict of interest statement

The authors declare that they have no competing interests.

© 2021. The Author(s).

Figures

Fig. 1
Fig. 1
Flowchart of the intervention study
Fig. 2
Fig. 2
The reward task wheel of fortune

References

    1. Aman M, Jason Y, Kaye A, Urman R. Evidence-based non-pharmacological therapies for fibromyalgia. Curr Pain Headache Rep. 2018;22(5):33. doi: 10.1007/s11916-018-0688-2.
    1. Baer RA, Smith GT, Hopkins J, Krietemeyer J, Toney L. Using self-report assessment methods to explore facets of mindfulness. Assessment. 2006;13(1):27–45. doi: 10.1177/1073191105283504.
    1. Baliki MN, Geha PY, Fields HL, Apkarian AV. Predicting value of pain and analgesia: nucleus accumbens response to noxious stimuli changes in the presence of chronic pain. Neuron. 2010;66(1):149–160. doi: 10.1016/j.neuron.2010.03.002.
    1. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4(6):561–571. doi: 10.1001/archpsyc.1961.01710120031004.
    1. Becker S, Gandhi W, Elfassy NM, Schweinhardt P. The role of dopamine in the perceptual modulation of nociceptive stimuli by monetary wins or losses. Eur J Neurosci. 2013;38:3080–3088. doi: 10.1111/ejn.12303.
    1. Bellato E, Marini E, Castoldi F, Barbasetti N, Mattei L, Bonasia DE, Blonna D. Fibromyalgia syndrome: etiology, pathogenesis, diagnosis, and treatment. Pain Res Treat. 2012;2012:426130–426117. doi: 10.1155/2012/426130.
    1. Bennett RM, Friend R, Jones KD, Ward R, Han BK, Ross RL. The Revised Fibromyalgia Impact Questionnaire (FIQR): validation and psychometric properties. Arthritis Res Ther. 2009;11(4):R120. doi: 10.1186/ar2783.
    1. Berding G, Burchert W, van den Hoff J, Pytlik C, Neukam FW, Meyer GJ, Hundeshagen H. Evaluation of the incorporation of bone grafts used in maxillofacial surgery with [18 F] fluoride ion and dynamic positron emission tomography. Eur J Nucl Med. 1995;22(10):1133-40.
    1. Bolger N, Laurenceau JP. Intensive longitudinal methods: an introduction to diary and experience sampling research. New York: Guilford Press; 2013.
    1. Brooks P, Boers M, Simon LS, Strand V, Tugwell P, Idzerda L. OMERACT 10--International Consensus Conference on Outcome Measures in Rheumatology Clinical Trials. J Rheumatol. 2011;38(7):1450–1451. doi: 10.3899/jrheum.110325.
    1. Brown GK, Nicassio PM. Development of a questionnaire for the assessment of active and passive coping strategies in chronic pain patients. Pain. 1987;31(1):53–64. doi: 10.1016/0304-3959(87)90006-6.
    1. Bryant F. Savoring Beliefs Inventory (SBI): a scale for measuring beliefs about savoring. J Mental Health. 2003;12(2):175–196. doi: 10.1080/0963823031000103489.
    1. Bushnell MC, Ceko M, Low LA. Cognitive and emotional control of pain and its disruption in chronic pain. Nat Rev Neurosci. 2013;14(7):502–511. doi: 10.1038/nrn3516.
    1. Buysse DJ, Reynolds III CF, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28(2):193-213.
    1. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore. 1994;23(2):129–138.
    1. Cohn MA, Fredrickson BL, Brown SL, Mikels JA, Conway AM. Happiness unpacked: positive emotions increase life satisfaction by building resilience. Emotion. 2009;9(3):361–368. doi: 10.1037/a0015952.
    1. de Jong M, Peeters F, Gard T, Ashih H, Doorley J, Walker R, et al. A randomized controlled pilot study on mindfulness-based cognitive therapy for unipolar depression in patients with chronic pain. J Clin Psychiatry. 2017. 10.4088/JCP.15m10160.
    1. Dillmann U, Nilges P, Saile H, Gerbershagen HU. Assessing disability in chronic pain patients. Schmerz. 1994;8(2):100–110. doi: 10.1007/BF02530415.
    1. Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007;39(2):175–191. doi: 10.3758/BF03193146.
    1. Fischer S, Doerr JM, Strahler J, Mewes R, Thieme K, Nater UM. Stress exacerbates pain in the everyday lives of women with fibromyalgia syndrome--the role of cortisol and alpha-amylase. Psychoneuroendocrinology. 2016;63:68–77. doi: 10.1016/j.psyneuen.2015.09.018.
    1. Froeliger B, Mathew AR, McConnell PA, et al. Restructuring reward mechanisms in nicotine addiction: a pilot fMRI study of mindfulness-oriented recovery enhancement for cigarette smokers. Evid Based Complement Alternat Med. 2017;2017:7018014–7018010. doi: 10.1155/2017/7018014.
    1. Gard DE, Gard MG, Kring AM, John OP. Anticipatory and consummatory components of the experience of pleasure: a scale development study. J Res Pers. 2006;40(6):1086-102.
    1. Garland EL, Roberts-Lewis A, Tronnier CD, Graves R, Kelley K. Mindfulness-Oriented Recovery Enhancement versus CBT for co-occurring substance dependence, traumatic stress, and psychiatric disorders: proximal outcomes from a pragmatic randomized trial [published correction appears in Behav Res Ther. 2018 Jan;100:78] Behav Res Ther. 2016;77:7–16. doi: 10.1016/j.brat.2015.11.012.
    1. Garland EL, Bryan CJ, Finan PH, Thomas EA, Priddy SE, Riquino MR, Howard MO. Pain, hedonic regulation, and opioid misuse: modulation of momentary experience by Mindfulness-Oriented Recovery Enhancement in opioid-treated chronic pain patients. Drug Alcohol Depend. 2017;173(Suppl 1):S65–S72. doi: 10.1016/j.drugalcdep.2016.07.033.
    1. Garland EL, Bryan CJ, Finan PH, Thomas EA, Priddy SE, Riquino MR, Howard MO. Pain, hedonic regulation, and opioid misuse: modulation of momentary experience by Mindfulness-Oriented Recovery Enhancement in opioid-treated chronic pain patients. Drug Alcohol Depend. 2017;173(Suppl 1):S65–S72. doi: 10.1016/j.drugalcdep.2016.07.033.
    1. Garland EL, Froeliger B, Howard MO. Effects of Mindfulness-Oriented Recovery Enhancement on reward responsiveness and opioid cue-reactivity. Psychopharmacology (Berl) 2014;231(16):3229–3238. doi: 10.1007/s00213-014-3504-7.
    1. Garland EL, Froeliger B, Howard MO. Neurophysiological evidence for remediation of reward processing deficits in chronic pain and opioid misuse following treatment with Mindfulness-Oriented Recovery Enhancement: exploratory ERP findings from a pilot RCT. J Behav Med. 2015;38(2):327–336. doi: 10.1007/s10865-014-9607-0.
    1. Garland EL, Froeliger B, Zeidan F, Partin K, Howard MO. The downward spiral of chronic pain, prescription opioid misuse, and addiction: cognitive, affective, and neuropsychopharmacologic pathways. Neurosci Biobehav Rev. 2013;37(10 Pt 2):2597–2607. doi: 10.1016/j.neubiorev.2013.08.006.
    1. Garland EL, Gaylord SA, Boettiger CA, Howard MO. Mindfulness training modifies cognitive, affective, and physiological mechanisms implicated in alcohol dependence: results of a randomized controlled pilot trial. J Psychoactive Drugs. 2010;42(2):177–192. doi: 10.1080/02791072.2010.10400690.
    1. Garland EL, Howard MO, Zubieta JK, Froeliger B. Restructuring hedonic dysregulation in chronic pain and prescription opioid misuse: effects of Mindfulness-Oriented Recovery Enhancement on responsiveness to drug cues and natural rewards. Psychother Psychosom. 2017;86(2):111–112. doi: 10.1159/000453400.
    1. Garland EL, Manusov EG, Froeliger B, Kelly A, Williams JM, Howard MO. Mindfulness-oriented recovery enhancement for chronic pain and prescription opioid misuse: results from an early-stage randomized controlled trial. J Consult Clin Psychol. 2014;82(3):448–459. doi: 10.1037/a0035798.
    1. Garland EL, Howard MO. Enhancing Natural Reward Responsiveness Among Opioid Users Predicts Chronic Pain Relief: EEG Analyses From a Trial of Mindfulness-Oriented Recovery Enhancement. J Soc Social Work Res. 2018;9(2):285-303. 10.1086/697685.
    1. Garland EL, Hanley AW, Riquino MR, Reese SE, Baker AK, Salas K, Yack BP, Bedford CE, Bryan MA, Atchley R, Nakamura Y, Froeliger B, Howard MO. Mindfulness-oriented recovery enhancement reduces opioid misuse risk via analgesic and positive psychological mechanisms: a randomized controlled trial. J Consult Clin Psychol. 2019;87(10):927–940. doi: 10.1037/ccp0000390.
    1. Garland EL, Hanley AW, Kline A, Cooperman NA. Mindfulness-Oriented Recovery Enhancement reduces opioid craving among individuals with opioid use disorder and chronic pain in medication assisted treatment: ecological momentary assessments from a stage 1 randomized controlled trial. Drug Alcohol Depend. 2019;203:61–65. doi: 10.1016/j.drugalcdep.2019.07.007.
    1. Garland EL, Atchley RM, Hanley AW, Zubieta JK, Froeliger B. Mindfulness-Oriented Recovery Enhancement remediates hedonic dysregulation in opioid users: neural and affective evidence of target engagement. Sci Adv. 2019;5(10):eaax1569. doi: 10.1126/sciadv.aax1569.
    1. Garland EL. Psychosocial intervention and the reward system in pain and opioid misuse: new opportunities and directions. Pain. 2020;161(12):2659-66. 10.1097/j.pain.0000000000001988.
    1. Garnefski N, Rieffe C, Jellesma F, Terwogt MM, Kraaij V. Cognitive emotion regulation strategies and emotional problems in 9-11-year-old children: the development of an instrument. Eur Child Adolesc Psychiatry. 2007;16(1):1–9. doi: 10.1007/s00787-006-0562-3.
    1. Geschwind N, Peeters F, Jacobs N, Delespaul P, Derom C, Thiery E, van Os J, Wichers M. Meeting risk with resilience: high daily life reward experience preserves mental health. Acta Psychiatr Scand. 2010;122(2):129–138. doi: 10.1111/j.1600-0447.2009.01525.x.
    1. Goldenberg DL, Burckhardt C, Crofford L. Management of fibromyalgia syndrome. JAMA. 2004;292(19):2388–2395. doi: 10.1001/jama.292.19.2388.
    1. Goyal M, Singh S, Sibinga EM, et al. Meditation programs for psychological stress and well-being: a systematic review and meta-analysis. JAMA Intern Med. 2014;174(3):357–368. doi: 10.1001/jamainternmed.2013.13018.
    1. Guillod, M., Gaillard, C., Recabarren, R., Schoebi, D., Merlo, M., Hasler, G., & Martin-Soelch, C. (2017). Measures of daily mood, stress and reward responses in offspring of depressed parents. Paper presented at the 13th Congress of the World Congress on Biological Psychiatry, Copenhagen.
    1. Hashmi JA, Baliki MN, Huang L, Baria AT, Torbey S, Hermann KM, Schnitzer TJ, Apkarian AV. Shape shifting pain: chronification of back pain shifts brain representation from nociceptive to emotional circuits. Brain. 2013;136(Pt 9):2751–2768. doi: 10.1093/brain/awt211.
    1. Hautzinger M. The Beck Depression Inventory in clinical practice. Nervenarzt. 1991;62(11):689–696.
    1. Hays RD, Stewart AL. Sleep measures. In: Stewart AL, Ware JE Jr, editors. Measuring functioning and well-being: the Medical Outcomes Study Approach. Durham (NC): Duke University Press; 1992. pp. 235–259.
    1. Heiss WD, Hilker R. The sensitivity of 18‐fluorodopa positron emission tomography and magnetic resonance imaging in Parkinson's disease. Eur J Neurol. 2004;11(1):5-12.
    1. Hipolito L, Wilson-Poe A, Campos-Jurado Y, Zhong E, Gonzalez-Romero J, Virag L, Whittington R, Comer SD, Carlton SM, Walker BM, Bruchas MR, Moron JA. Inflammatory pain promotes increased opioid self-administration: role of dysregulated ventral tegmental area mu opioid receptors. J Neurosci. 2015;35(35):12217–12231. doi: 10.1523/JNEUROSCI.1053-15.2015.
    1. Jones GT, Atzeni F, Beasley M, Fluss E, Sarzi-Puttini P, Macfarlane GJ. The prevalence of fibromyalgia in the general population: a comparison of the American College of Rheumatology 1990, 2010, and modified 2010 classification criteria. Arthritis Rheumatol. 2015;67(2):568–575. doi: 10.1002/art.38905.
    1. Laux LG, P. Das State Trait Angstinventar. Beltz: Weinheim; 1981.
    1. Ledermann K, Jenewein J, Sprott H, Hasler G, Schnyder U, Warnock G, Johayem A, Kollias S, Buck A, Martin-Soelch C. Altered dopamine responses to monetary rewards in female fibromyalgia patients with and without depression: a [11C] raclopride bolus-plus-infusion PET study. Psychotherapy and psychosomatics. 2017;86(3):181–182. doi: 10.1159/000455927.
    1. Ledermann K, Jenewein J, Sprott H, Hasler G, Schnyder U, Warnock G, Johayem A, Kollias S, Buck A, Martin-Soelch C. Relation of dopamine receptor 2 binding to pain perception in female fibromyalgia patients with and without depression--a [(1)(1)C] raclopride PET-study. Eur Neuropsychopharmacol. 2016;26(2):320–330. doi: 10.1016/j.euroneuro.2015.12.007.
    1. Loch N, Hiller W, Witthöft M. Der cognitive emotion regulation questionnaire (CERQ). Zeitschrift für Klinische Psychologie und Psychotherapie. 2011.
    1. Loggia ML, Berna C, Kim J, Cahalan CM, Gollub RL, Wasan AD, Harris RE, Edwards RR, Napadow V. Disrupted brain circuitry for pain-related reward/punishment in fibromyalgia. Arthritis Rheumatol. 2014;66(1):203–212. doi: 10.1002/art.38191.
    1. McNair DM, Lorr M, Droppleman LF. Manual for the profile of mood states (POMS). San Diego: Educational and Industrial Testing Service; 1971.
    1. Mulder M, Koopmans G, Wassink G, Al Mansouri G, Simard ML, Havekes LM, Prickaerts J, Blokland A. LDL receptor deficiency results in decreased cell proliferation and presynaptic bouton density in the murine hippocampus. Neurosci Res. 2007;59(3):251-6. 10.1016/j.neures.2007.07.004.
    1. Muthén, L. K., & Muthén, B. O. ((1998-2012)). Mplus user’s guide. 7th edition. Los Angeles, CA: Muthén & Muthén.
    1. Niikura K, Narita M, Butelman ER, Kreek MJ, Suzuki T. Neuropathic and chronic pain stimuli downregulate central mu-opioid and dopaminergic transmission. Trends Pharmacol Sci. 2010;31(7):299–305. doi: 10.1016/j.tips.2010.04.003.
    1. O'Doherty JP. Reward representations and reward-related learning in the human brain: insights from neuroimaging. Curr Opin Neurobiol. 2004;14(6):769–776. doi: 10.1016/j.conb.2004.10.016.
    1. Penrod JR, Bernatsky S, Adam V, Baron M, Dayan N, Dobkin PL. Health services costs and their determinants in women with fibromyalgia. J Rheumatol. 2004;31(7):1391–1398.
    1. Potvin S, Grignon S, Marchand S. Human evidence of a supra-spinal modulating role of dopamine on pain perception. Synapse. 2009;63(5):390–402. doi: 10.1002/syn.20616.
    1. Rosenzweig S, Greeson JM, Reibel DK, Green JS, Jasser SA, Beasley D. Mindfulness-based stress reduction for chronic pain conditions: variation in treatment outcomes and role of home meditation practice. J Psychosom Res. 2010;68(1):29–36. doi: 10.1016/j.jpsychores.2009.03.010.
    1. Schwartz CE, Chesney MA, Irvine MJ, Keefe FJ. The control group dilemma in clinical research: applications for psychosocial and behavioral medicine trials. Psychosom Med. 1997;59(4):362–371. doi: 10.1097/00006842-199707000-00005.
    1. Skevington SM, Lotfy M, O'Connell KA, Group, W The World Health Organization’s WHOQOL-BREF quality of life assessment: psychometric properties and results of the international field trial. A report from the WHOQOL group. Qual Life Res. 2004;13(2):299–310. doi: 10.1023/B:QURE.0000018486.91360.00.
    1. Stewart AL, Hays RD, Ware JE., Jr The MOS short-form general health survey. Reliability and validity in a patient population. Med Care. 1988;26(7):724–735. doi: 10.1097/00005650-198807000-00007.
    1. Taylor AM, Becker S, Schweinhardt P, Cahill C. Mesolimbic dopamine signaling in acute and chronic pain: implications for motivation, analgesia, and addiction. Pain. 2016;157(6):1194–1198. doi: 10.1097/j.pain.0000000000000494.
    1. Theadom A, Cropley M, Smith HE, Feigin VL, McPherson K. Mind and body therapy for fibromyalgia. Cochrane Database Syst. Rev. 2015;4(8):CD001980. doi: 10.1002/14651858.CD001980.pub3.
    1. Thieme K, Mathys M, Turk DC. Evidenced-based guidelines on the treatment of fibromyalgia patients: are they consistent and if not, why not? Have effective psychological treatments been overlooked? J Pain. 2016;18(7):747–756. doi: 10.1016/j.jpain.2016.12.006.
    1. Thieme K, Mathys M, Turk DC. Evidenced-based guidelines on the treatment of fibromyalgia patients: are they consistent and if not, why not? Have effective psychological treatments been overlooked? J Pain. 2017;18(7):747–756. doi: 10.1016/j.jpain.2016.12.006.
    1. The WHOQOL Group. Development of the World Health Organization WHOQOL-BREF quality of life assessment. Psychol Med. 1998;28(3):551-8. 10.1017/s0033291798006667.
    1. Veehof MM, Trompetter HR, Bohlmeijer ET, Schreurs KM. Acceptance- and mindfulness-based interventions for the treatment of chronic pain: a meta-analytic review. Cogn Behav Ther. 2016;45(1):5–31. doi: 10.1080/16506073.2015.1098724.
    1. Ware JE, Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36) I. Conceptual framework and item selection. Med Care. 1992;30(6):473–483. doi: 10.1097/00005650-199206000-00002.
    1. Wilhelm P, Schoebi D. Assessing mood in daily life. European Journal of Psychological Assessment. 2007;23(4):258–267. doi: 10.1027/1015-5759.23.4.258.
    1. Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Hauser W, Katz RS, et al. Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR Preliminary Diagnostic Criteria for Fibromyalgia. J Rheumatol. 2011;38(6):1113–1122. doi: 10.3899/jrheum.100594.
    1. Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, Mease P, Russell AS, Russell IJ, Winfield JB, Yunus MB. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res (Hoboken) 2010;62(5):600–610. doi: 10.1002/acr.20140.
    1. Wood PB, Patterson JC, 2nd, Sunderland JJ, Tainter KH, Glabus MF, Lilien DL. Reduced presynaptic dopamine activity in fibromyalgia syndrome demonstrated with positron emission tomography: a pilot study. J Pain. 2007;8(1):51–58. doi: 10.1016/j.jpain.2006.05.014.
    1. Wood PB, Schweinhardt P, Jaeger E, Dagher A, Hakyemez H, Rabiner EA, Bushnell MC, Chizh BA. Fibromyalgia patients show an abnormal dopamine response to pain. Eur J Neurosci. 2007;25(12):3576–3582. doi: 10.1111/j.1460-9568.2007.05623.x.
    1. Zautra AJ, Fasman R, Reich JW, Harakas P, Johnson LM, Olmsted ME, Davis MC. Fibromyalgia: evidence for deficits in positive affect regulation. Psychosom Med. 2005;67(1):147–155. doi: 10.1097/01.psy.0000146328.52009.23.
    1. Zautra AJ, Johnson LM, Davis MC. Positive affect as a source of resilience for women in chronic pain. J Consult Clin Psychol. 2005;73(2):212–220. doi: 10.1037/0022-006X.73.2.212.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi